Clinical trial · Interventional
[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
Clinical Application of Dual-target Imaging Agent [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Preclinical studies have confirmed that \[68Ga\]Ga-P17-079 in both mouse prostate tumors and osseogenic metastases has high uptake and prolonged retention, which enables \[68Ga\]Ga-P17-079 to be fully absorbed by the lesions, and it is possible to detect bone metastases, prostate cancer primary sites, lymph node metastases and organ metastases at the same time in a single examination. It is a potential "killing two birds with one stone" imaging agent. At this stage, the clinical study of \[68Ga\]Ga-P17-079 in the diagnosis and treatment of metastatic prostate cancer as a self-made preparation is planned to be carried out in our hospital to further verify its clinical application value.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Cancer (mPC) | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| P17-079, P16-093, or P15-041 PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- P17-079+P16-093
- interventionNames
- Diagnostic Test: P17-079, P16-093, or P15-041 PET/CT
- type
- EXPERIMENTAL
- label
- P17-079+P15-041
- interventionNames
- Diagnostic Test: P17-079, P16-093, or P15-041 PET/CT
Primary outcomes (1)
- measure
- SUV
- timeFrame
- 0-180 min post-injection
- description
- measured by PET/CT
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Male aged 18-85 years, expected survival ≥12 weeks. * Patients who have not undergone chemoradiotherapy, feasible surgery or biopsy to obtain a pathological diagnosis or are highly suspected of malignancy according to clinical diagnostic criteria. * At least one measurable target lesion was present according to RECIST1.1 criteria. * Obtain written informed consent and be able to follow up Exclusion Criteria: * Severe abnormal liver and kidney function * Fertile subjects will need to use effective contraception during the study * Unable to lie flat for half an hour * Refused to join this clinical investigator * Suffering from claustrophobia or other mental illness * Other conditions deemed unsuitable for participation in the trial
References
Publications (0)
Data not yet available